Takeda Drug Shows Ability To Reduce Tumor Growth Rate
This article was originally published in PharmAsia News
Executive Summary
A drug of Takeda Pharmaceuticals has demonstrated effectiveness in reducing the rate of growth of tumors, at least in mice. Takeda, which acquired the MLN4924 when it bought Millennium Pharmaceuticals, has begun human clinical trials as a result of the findings. The new drug, although similar to Takeda's Velcade (bortezomib) for treating blood cancer, differs in that it attacks a different enzyme that regulates the proteins that cancer cells rely on to grow. The new version blocks the process that regulates how some proteins are broken down. (Click here for more
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.